Skip to search formSkip to main contentSkip to account menu

ioxilan

Known as: Ioxilane, Ioxilanum, N-(2,3-dihydroxypropyl)-N'-(2- hydroxyethyl)-5-[N-(2,3-dihydroxypropyl) acetamido]-2,4,6-triiodoisophthal-amide 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2015
Review
2015
Objective The use of cone beam imaging during neurointerventional procedure has been increasing rapidly. Initially used as a CT… 
2009
2009
OBJECTIVE To observe the effects of excipient on the sterile stability of Ioxilan Injection. METHODSThe pH values,free iodide… 
2007
2007
  • Y. Liu
  • 2007
  • Corpus ID: 101355149
Objective:To study the kinetics of degradation of ioxilan injection under 4 500 lx light.Methods:The iodide ion concentration… 
2007
2007
Ioxilan, a non-ionic X-ray contrast agent, was synthesized from 5-acetamido-3-[(2- hydroxyethylamino)carbonyl]-2,4,6… 
2006
2006
The molecular weight of ioxilan is 791.12 and the organically bound iodine content is 48.1%. Ioxilan is nonionic and does not… 
2001
2001
AbstractBackground. Nephrotoxicity is a well-known adverse effect of radiographic contrast medium (CM). Recently, several kinds… 
1988
1988
Foster SJ, Sovak M. Isomerism in iohexhol and ioxilan: Analysis and implications. Invest Radiol 1988;23(Suppl 1):S106‐S109… 
1988
1988
Thomsen HS, Dorph S, Mygind T, Hemmingsen L, Holm J, Larsen S, Nielsen H, Rygaard H, Skaarup P. Urine profiles following… 
1988
1988
Thomsen HS, Dorph S, Mygind T, Nielsen H, Rygaard H, Larsen S, Skaarup P, Hemmingsen L, Holm J. Do contrast media aggravate…